Kairos Pharma Shares to Reverse Split on Tuesday, September 1st (NYSEAMERICAN:KAPA)

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA)’s stock is going to reverse split before the market opens on Tuesday, September 1st. The 1-7 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, August 31st.

Kairos Pharma Stock Down 20.0%

KAPA stock traded down $0.06 during trading on Monday, hitting $0.23. 1,701,340 shares of the company’s stock traded hands, compared to its average volume of 1,091,567. Kairos Pharma has a 1 year low of $0.22 and a 1 year high of $2.11. The business has a fifty day simple moving average of $0.35 and a two-hundred day simple moving average of $0.49. The firm has a market capitalization of $5.50 million, a P/E ratio of -0.83 and a beta of 1.56.

Kairos Pharma (NYSEAMERICAN:KAPA) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.06) EPS for the quarter. On average, equities research analysts predict that Kairos Pharma will post -0.37 EPS for the current fiscal year.

Hedge Funds Weigh In On Kairos Pharma

An institutional investor recently bought a new position in Kairos Pharma stock. XTX Topco Ltd acquired a new position in Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 62,746 shares of the company’s stock, valued at approximately $44,000. XTX Topco Ltd owned approximately 0.31% of Kairos Pharma at the end of the most recent reporting period.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.